Loading clinical trials...
Loading clinical trials...
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of [225Ac]Ac-A9-3408 in Subjects With Unresectable or Metastatic Melanoma
Conditions
Interventions
[225Ac]Ac-A9-3408
[68Ga]Ga-A9T-3202
Locations
4
Australia
Alfred Health
Melbourne, Victoria, Australia
Austin Health
Melbourne, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
GenesisCare Murdoch
Murdoch, Western Australia, Australia
Start Date
November 19, 2025
Primary Completion Date
January 1, 2028
Completion Date
January 1, 2028
Last Updated
March 16, 2026
NCT05111574
NCT06999980
NCT07230613
NCT07136181
NCT04318717
NCT06889610
Lead Sponsor
Alpha-9 Oncology USA Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions